StreetAlpha.app
Home › Stocks › GANX

Gain Therapeutics, Inc. (GANX)

$1.00
▼ −4.82%
LAST CLOSE · NOV 20

Gain Therapeutics develops small molecule drugs for neurological and rare genetic diseases, based in Bethesda, Maryland. It last closed at $1.00 on Nov 20, down 4.82% on the day. The next earnings report for GANX is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, GANX reported EPS of -$0.07. Over its last 8 reports the stock moved an average of 3.0% the session after earnings.

AI Auto Pilots
Is GANX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GANX.

Key Stats

Last 12 months
Results
Net income
−$18.0M
EPS (diluted)
−$0.42
Valuation
Market cap
$44.5M
44.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.7M
At Sep 30
Debt
$309K
At Sep 30
Shareholder equity
$10.2M
Shares outstanding
44.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$13.9M−$13.9MFY2021FY2022: −$17.6M−$17.6MFY2022FY2023: −$22.3M−$22.3MFY2023FY2024: −$20.4M−$20.4MFY2024FY2025: −$20.2M−$20.2MFY2025

From GANX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · After the close
Reported EPS
-$0.07
Quarter ended Sep 2026
Year ago EPS
-$0.15
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.11Dec '24Mar 2025: -$0.16Mar '25Jun 2025: -$0.19Jun '25Sep 2025: -$0.15Sep '25Dec 2025: -$0.11Dec '25Mar 2026: -$0.13Mar '26Jun 2026: -$0.11Jun '26Sep 2026: -$0.07Sep '26Latest -$0.07
Revenue by quarter
Not enough quarters on file yet.
How GANX moved after its last 8 reports
Average move the session after a report ±3.0%
Nov 10, 2026After the close+2.8%
Aug 11, 2026After the close+2.9%
May 11, 2026After the close−1.1%
Mar 26, 2026After the close−3.2%
Nov 12, 2025After the close+1.4%
Aug 12, 2025After the close+1.3%
May 14, 2025After the close−2.7%
Mar 27, 2025After the close−8.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GANXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GANX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GANX

Technical Analysis

GANX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 10% below its 20 day and 40% below its 50 day average. It is 80% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $0.95, and the nearest resistance the Pivot at $1.02.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 12.7%/day
Key levels
$4.3452 week high+334.0%
$1.80200 day average+80.0%
$1.61100 day average+61.0%
$1.4050 day average+40.0%
$1.18Swing high (Nov 10)+18.0%
$1.0920 day average+9.0%
$1.08Pivot R1+8.0%
$1.02Pivot+2.0%
$1.00Last close
$0.95Pivot S1−5.0%
$0.9452 week low−6.0%
$0.94Swing low (Nov 5)−6.0%
Indicators
RSI (14)39.03Weak, oversold below 30Neutral
MACD-0.09Above its signal lineBullish
Stochastic31.4Middle of its rangeNeutral
ADX (14)26.9Trending down
Williams %R-83.5Oversold below −80, overbought above −20Oversold
CCI (20)-100.5Oversold below −100, overbought above 100Oversold
Rate of change−3.0%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 12.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GANX

What happened before

See how GANX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GANX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GANX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GANXHow many large options trades hit GANX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

GANX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●19 buying vs 21 selling
  • ▼Held by funds -1.8 pts
  • ●Funds holding +0
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding50500.0%
In funds' top 1000–
Held by funds19.0%20.7%−1.8 pts
New / increased9 / 1012 / 15−29.6%
Reduced / sold out11 / 109 / 4+61.5%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GANX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GANX is in one of them and how their past GANX trades turned out.

GANX in the AI portfolios
Loading…

GANX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GANX in an article yet. Here's the latest on the wider market.

GANX in the news

About Gain Therapeutics

Gain Therapeutics is a biotechnology company in Bethesda, Maryland, that develops small molecule drugs for diseases caused by misfolded proteins. Its lead candidate, GT-02287, is being tested for Parkinson's disease. The company is also working on treatments for lysosomal storage disorders, metabolic disorders and oncology. It uses its Magellan computational platform to find sites on disease-linked proteins where drugs can bind and to design molecules that fit those sites.

Headquarters
Bethesda, MD